An endothelin antagonist for resistant hypertension

Research output: Contribution to journalLetter

Abstract

I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.
Original languageEnglish
Pages (from-to)636-636
Number of pages1
JournalThe Lancet
Volume375
Issue number9715
DOIs
Publication statusPublished - 22 Feb 2010
Externally publishedYes

    Fingerprint

Cite this